European journal of nuclear medicine and molecular imaging
Impact of disease-modifying therapy on [99mTc]Tc-DPD SPECT/CT markers in transthyretin cardiac amyloidosis enabled by artificial intelligence.
Clemens P Spielvogel, Markus Köfler, Zewen Jiang, Jing Ning, Josef Yu, David Haberl, Christina Kronberger, Michael Poledniczek, Lena Marie Schmid, David Kersting, Nikita Ermolaev, Roza B Eslam, Michaela Auer-Grumbach, Christina Binder, Franz Duca
Published: 202510.1007/s00259-025-07673-6
Abstract
PURPOSE: Transthyretin cardiac amyloidosis (ATTR-CM) is a progressive, underdiagnosed disease with high morbidity and mortality. While disease-modifying therapies (DMTs) slow progression, early treatment response markers remain scarce. This study ass…
Preview only. Read the full abstract at the source